SCHEMBL5065447

SCHEMBL5065447

CSc1ncnc2sc(C)nc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.50
LMNA P02545 3/20 0.50
HPGD P15428 3/20 0.36
HSD17B10 Q99714 4/20 0.33
TP53 P04637 1/20 0.33
CYP1A2 P05177 1/20 0.33
TSHR P16473 1/20 0.33
ICAM1 P05362 1/20 0.33
SELE P16581 1/20 0.33
VCAM1 P19320 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
MAPT P10636 2/20 0.33
MAPK1 P28482 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
NOTUM Q6P988 5/20 0.32
CSNK2A2 P19784 2/20 0.32
CSNK2B P67870 2/20 0.32
CSNK2A1 P68400 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14959701 0.76 CHRM4 (0.39) ALDH1A1LMNAHPGDHSD17B10TP53
SCHEMBL4800416 0.76 ALDH1A1 (0.41) ALDH1A1LMNAHSD17B10TP53CYP1A2
SCHEMBL4801016 0.76 ALDH1A1 (0.41) ALDH1A1LMNAHPGDHSD17B10TP53
SCHEMBL5064157 0.75 ALDH1A1 (0.41) ALDH1A1LMNACYP1A2TSHRNOTUM
SCHEMBL5458654 0.75 ALDH1A1 (0.41) ALDH1A1LMNANOTUMCSNK2A2CSNK2B
SCHEMBL20857368 0.74 KDM4E (0.38) ALDH1A1LMNAHPGDHSD17B10TSHR
SCHEMBL5067504 0.74 ALDH1A1 (0.40) ALDH1A1LMNAMEN1KMT2ATDP1
SCHEMBL9545445 0.73 ADORA3 (0.54) HSD17B10SELEVCAM1KMT2ASMN1; SMN2
SCHEMBL14188344 0.73 PIK3CD (0.51) ALDH1A1HPGDHSD17B10MAPTCSNK2A1
SCHEMBL5065405 0.72 HSD17B10 (0.44) ALDH1A1LMNAHSD17B10TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
US-20080269238-A1 Thiazolopyrimidine Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-10-30 US disclosed
EP-1731523-A1 THIAZOLOPYRIMIDINE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2006-12-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269238-A1 Thiazolopyrimidine Derivative FGFR3, FGFR1, ERBB3 ALDH1A1 1911/4885LMNA 4401/4885HPGD 2105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.